Advertisement

Sozial- und Präventivmedizin

, Volume 43, Issue 3, pp 167–172 | Cite as

European Medical Association Smoking or Health (EMASH)-Konsensuspapier Rauchertherapie: Richtlinien für Ärzte

  • Ursula Kunze
  • Anita Schmeiser-Rieder
  • Rudolf Schoberberger
Technical Report

Zusammenfassung

Die hier vorliegende Arbeit fasst die aktuellen Erkenntnisse und therapeutischen Möglichkeiten der Rauchertherapie zusammen. Diese Richtlinien wurden von Experten der EMASH (European Medical Association Smoking or Health) erarbeitet. Die gezielte Diagnostik und Therapie der Nikotinabhängigkeit sind wesentliche Bestandteile einer erfolgreichen Abstinenz. Die Diagnostik mit Hilfe des Fagerström Tests zur Erhebung der Nikotinabhängigkeit (FTND) und die Möglichkeiten der Nikotinersatztherapie (Kaugummi, Pflaster, Nasenspray und Inhaler) werden genau erklärt. Zudem werden neue Symptome der Nikotinabhängigkeit beschrieben, die eine noch genauere Diagnostik ermöglichen (Nocturnal Sleep Disturbing Nicotine Craving, Nicotine Pre-Abstinence Syndrome).

Smoking cessation: EMASH consensus

Summary

The present study summarizes the latest scientific findings on smoking cessation and the various therapeutic possibilities. The guidelines presented here were compiled by the experts of EMASH (European Medical Association Smoking or Health). Accurate diagnosis and adequate treatment of nicotine dependence is essential for achieving sustained abstinence. Diagnostic procedures including the Fagerström Test for Nicotine Dependence (FTND) and various modes of nicotine replacement therapy (chewing gum, plaster, nasal spray and inhaler) are described. New symptoms of nicotine dependence (nocturnal sleep disturbing nicotine craving, nicotine pre-abstinence syndrome), that permit a more precise diagnosis, are discussed.

Arrêt du tabagsisme: Recommandations EMASH

Résumé

Ce travail synthétise les connaissances et les possibilités thérapeutiques actuelles concernant la prise en charge des fumeurs. Ces recommendations ont été élaborées par des experts de l'EMASH (European Medical Association Smoking or Health). Un diagnostic ciblé ainsi qu'un traitement de la dépendance à la nicotine sont essentiels pour parvenir à une abstinence définitive. La méthode du diagnostic de dépendance à la nicotine (FTND) à l'aide du test Fagerström, et les possibilités d'une thérapie de remplacement de la nicotine (chewing-gum, patch, spray nasal et inhalateur0 sont décrites de façon détaillée. En outre, de noveaux symptômes de dépendance de la nicotine sont décrits, permettant un diagnostic encore plus précis (nocturnal sleep disturbing nicotine craving, nicotine pre-abstinence syndrome).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literaturverzeichnis

  1. 1.
    Salto E, Nardini S, Cornuz J et al. Guidelines on Smoking Cessation for General Practitioners and other Health Professionals. European Medical Newsletter on Smoking Cessation 1997;15:2–6.Google Scholar
  2. 2.
    Kunze M, Schoberberger R, Abelin T et al. Rauchertherapie: Konsensus in den deutschsprachigen Ländern. Soz Präventivmed 1992;37:223–230.Google Scholar
  3. 3.
    WHO, A 5 year action plan. World Health Organization, Regional Office for Europe, Kopenhagen, 1988.Google Scholar
  4. 4.
    Schoberberger R, Kunze U, Schmeiser-Rieder A. Diagnostik und Therapie der Nikotinabhängigkeit. Versicherungsmedizin 1997;49:25–29.Google Scholar
  5. 5.
    Kunze M, Vutuc C. Threshold of Tar Exposure: Analysis of Smoking History of Male Lung Cancer Cases and Controls. In: Gori GB, Bock FG eds. Banbury Report 3: A Safe Cigarette? 1980: 29–34.Google Scholar
  6. 6.
    Kunze U, Schoberberger R, Fagerström KO, Aigner K, Bölcskei P, Dittrich C. High Nicotine Dependence among Lung Cancer Patients. The European Respiratory Journal 1996;9:23.Google Scholar
  7. 7.
    Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991;86: 1119–1127.Google Scholar
  8. 8.
    Schoberberger R. Psychological and physiological dependence. Vortrag anlässlich der 3rd International Conference on Preventive Cardiology. Oslo, 1993.Google Scholar
  9. 9.
    Fagerström KO, Kunze M, Schoberberger R et al. Nicotine dependence versus smoking prevalence: comparisons among countries and categories of smokers. Tobacco Control 1996;6:52–56.Google Scholar
  10. 10.
    Schmeiser-Rieder A, Schoberberger R, Kunze U, Kunze M. Nocturnal sleep disturbing nicotine craving (NSDNC). Abstractband-Annual Scientific Conference of the Society for Research on Nicotine and Tobacco. Society for Research on Nicotine and Tobacco, 1996: 42.Google Scholar
  11. 11.
    Prochaska J, DiClemente C. Self-change progress, self-efficacy and decisional balance across five stages of smoking cessation. In: Engstrom P ed. Advances in cancer control, 1993:131–140.Google Scholar
  12. 12.
    Batra A, Fagerström KO. Neue Aspekte der Nikotinabhängigkeit und Raucherentwöhnung. Sucht 1997;4:277–288.Google Scholar
  13. 13.
    Tang JL, Law M, Wald N. How effective is nicotine replacement therapy in helping people to stop smoking? Br Med J 1994;308:21–26.Google Scholar
  14. 14.
    Fiore MC, Cohen SJ, Goldstein MG et al. Smoking cessation. Clinical Practice Guideline 1996; No 18, AHCPR 96-0692. US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research.Google Scholar
  15. 15.
    Silagy C, Mant D, Fowler G, Iodge M. Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet 1994;343:139–142.Google Scholar
  16. 16.
    Henningfield JE. Nicotine medications for smoking cessation. N Engl J Med 1995;18:1196–1203.Google Scholar
  17. 17.
    Fagerström KO. Efficacy of nicotine chewing gum: a review: In: Nicotine replacement: A Critical Evaluation. Pomerlau O and Pomerlau CS eds. New York: Alan R. Liss, 1988:109–128.Google Scholar
  18. 18.
    Hughes JR. Pharmacotherapy for smoking cessation: unvalidated assumptions, anomalies and suggestions for future research. J Consult Clin Psychol 1993;61:751–760.Google Scholar
  19. 19.
    Tonnesen P. Nicotine Replacement and Other Drugs in Smoking Cessation. In: Bolliger CT, Fagerström KO. eds. The Tobacco Epidemic. Progress in Respiratory Research. 1997;28:178–189.Google Scholar
  20. 20.
    Fagerström KO, Sachs DPL. Medical management of tobacco dependence: a critical review of nicotine skin patches. Curr Pulmonol 1995;16:223–228.Google Scholar
  21. 21.
    Balfour DJK, Fagerström KO. Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders. Pharmacol Ther 1996;10:1–30.Google Scholar

Copyright information

© Birkhäuser Verlag 1998

Authors and Affiliations

  • Ursula Kunze
    • 1
  • Anita Schmeiser-Rieder
    • 1
  • Rudolf Schoberberger
    • 1
  1. 1.EMASH Scientific CenterInstitut für Sozialmedizin der Universität WienWien

Personalised recommendations